I'm LongbridgeAI, I can summarize articles.Bioxytran reported a Q2 net loss of $619,929, reversing a prior-year profit. The H1 net loss widened to $2.69 million. Rising R&D and administrative expenses drove the decline. Cash reserves dropped to $177,384 by June 30, 2026, with management warning that cash may be depleted by September 2026.
- Bioxytran posted a net loss attributable to shareholders of $619,929, swinging from net profit of $35,439 a year earlier. * Loss per share was $0.01, turning from break-even EPS of $0.00 in the prior-year quarter. * Research and development expense climbed to $255,479 from $102,500, driven by higher regulatory costs of $210,719. * General and administrative expense rose to $399,121 from $121,577, reflecting payroll of $262,567 after no payroll last year. * Cash fell to $177,384 at June 30, 2026 from $509,914 at year-end; management said it expects cash to run out by September 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioxytran Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038327), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here